Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04141 (
granulocyte-macrophage colony-stimulating factor
)
6,790
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Patients rendered T cell-deficient by advanced disease due to human immunodeficiency virus, an underlying neoplastic disorder, or immunosuppressive therapy are vulnerable to a select group of opportunistic infections. These infections, which often fail to respond to conventional therapy, provide the clinical setting in which the efficacy of treatment with cytokines can be tested. Particularly pertinent cytokines are those that activate macrophages and monocytes or enhance T-cell function. Experimental observations and emerging data from patients with intact T-cell function suggest that treatment with at least three cytokines, interferon-gamma,
interleukin-2
, and
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) may be of benefit. Each of these cytokines is already in clinical use, and each has therapeutic potential in a variety of different infectious disease. Patients with infections caused by opportunistic intracellular pathogens appear to be the most appropriate candidates for adjunctive cytokine therapy.
...
PMID:Cytokines as antimicrobial therapy for the T cell-deficient patient: prospects for treatment of nonviral opportunistic infections. 827 6
Phorbol myristate acetate (PMA) treatment of an EL-4 thymoma cell line (EL-4FARRAR) induced secretion of a factor that inhibited intracellular killing of Leishmania major amastigotes by activated macrophages. Analysis of the cytokines produced by EL-4 cells after PMA stimulation identified
interleukin-2
(IL-2, 2500 U/ml), IL-4 (1280 U/ml), interferon-gamma (IFN-gamma; 100 U/ml), and
granulocyte-macrophage colony-stimulating factor
(GM-CSF; 50 U/ml). Neither tumor necrosis factor nor transforming growth factor beta (TGF-beta) was detected. Each of the cytokines present in EL-4 fluids was assessed for capacity to activate macrophages for destruction of parasites or to suppress intracellular killing. IFN-gamma and GM-CSF both activated macrophages to kill Leishmania; IL-2 and IL-4 had no activity for induction of this antimicrobial effector function. IL-2 and IL-4 were tested for their capacity to inhibit lymphokine- or IFN-gamma-induced destruction of L. major by macrophages: IL-4 was ineffective, but IL-2 markedly suppressed the activation of macrophages for intracellular killing. Addition of > or = 10 U/ml of IL-2 at the time of infection, or up to 4 h before, blocked up to 100% of the capacity of activated macrophages to kill intracellular amastigotes. Immunoaffinity treatment of EL-4 fluids with anti-IL-2 antibody resulted in > 80% reduction in suppression of intracellular killing. The suppressive effects of IL-2 were not direct, but mediated by TGF-beta. IL-2 induced resident peritoneal macrophages to secrete > 5000 pg/ml TGF-beta 1, a quantity that is > 500-fold higher than constitutive background levels (20-40 pg/ml) and is sufficient to block intracellular killing activities. This increase in secretion of TGF-beta was not dependent increases in TGF-beta 1 mRNA. Treatment of cultures with EL-4 fluids or recombinant IL-2 in the presence of antibody to TGF-beta 1 blocked the suppressive activity of both. Thus, IL-2 was the major suppressor factor in EL-4 fluids, and it acted indirectly through the induction and autocrine action of TGF-beta.
...
PMID:Interleukin-2 suppresses activated macrophage intracellular killing activity by inducing macrophages to secrete TGF-beta. 828 43
Tumor-infiltrating lymphocytes (TILs) can mediate tumor regression in selected patients with advanced cancer. To study some of the physiological changes associated with TIL administration, hemodynamic effects were measured while 2 x 10(10) to 20 x 10(10) TILs (mean 10 +/- 1 x 10(10)) were infused into 22 patients. In 10 patients, the first bag of TILs was administered without any
interleukin-2
(
IL-2
) in the infusion bag; subsequent bags in the same patients and all bags in the next 12 patients contained
IL-2
in low concentrations (300,000 IU). Two hours following infusion (as compared with baseline), patients developed tachycardia (110 +/- 3.3 vs. 76 +/- 3.5 beats/min; p < 0.001), increased cardiac index (4.9 +/- 0.2 vs. 3.2 +/- 0.13 L/min/m2; p < 0.001), decreased systemic vascular resistance (677 +/- 37 vs. 1185 +/- 63 dyn/s/cm5; p < 0.001), and increased pulmonary artery diastolic pressure (15.9 +/- 1.4 vs. 10.6 +/- 1.1 mm Hg; p = 0.002). No significant changes in systemic blood pressure were noted. Analysis of data obtained in the 10 patients after infusion of the first bag of TILs (4.5 +/- 0.4 x 10(10)) without
IL-2
present in the infusate revealed similar, though less severe, changes. No significant correlation was noted between in vitro production of tumor necrosis factor-alpha, interferon-gamma, and
granulocyte-macrophage colony-stimulating factor
by TILs and hemodynamic effects when administered to patients. These results indicate that TIL infusion can cause hemodynamic changes similar to those previously reported in patients undergoing
IL-2
therapy.
...
PMID:Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients. 833 12
The influence of pooled human IgG preparations for intravenous use (i.v.Ig) on in vitro-induced cytokine production was studied at the single-cell level using cytokine-specific monoclonal antibodies (mAb) and indirect immunofluorescent technique. Cultured mononuclear cells from peripheral blood from healthy adult donors were polyclonally stimulated for 96 hr by either direct ligation of T-cell receptors using immobilized anti-CD3 mAb or by a combination of a protein kinase C activator [phorbol 12-myristate 13-acetate (PMA)] and a calcium ionophore (ionomycin) in the absence or presence of i.v.Ig. A marked inhibition of proliferation and blast transformation was noted in all i.v.Ig exposed cultures, despite good cell survival. The production of the T-cell lymphokines
interleukin-2
(
IL-2
), IL-10,interferon-gamma (IFN-gamma) and tumour necrosis factor-beta (TNF-beta) was significantly down-regulated during the whole studied period in the i.v.Ig containing anti-CD3 stimulated cultures. The synthesis of the monokine IL-8 was not suppressed and that of TNF-alpha, which was made by both lymphocytes and monocytes, was only moderately inhibited. Somewhat different and more transient effects were observed in the i.v.Ig-exposed PMA/ionomycin-activated cultures. The production of
IL-2
, IL-3, IL-4, IL-5, IL-10, TNF-beta and
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) was down-regulated during the initial phase of the cultures up to 48 hr, but not at 48-96 hr. The synthesis of IFN-gamma and TNF-alpha was unaffected of the influence of i.v.Ig during the entire culture period. The expression of
IL-2
receptors (IL-2R) was significantly suppressed in the i.v.Ig-treated anti-CD3-activated cells, but not in the PMA/ionomycin-stimulated cultures. Taken together our results indicate that pooled IgG may mediate immunomodulation by direct effects on cytokine production and on T-cell proliferation.
...
PMID:Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. 834
Attempts have been made to isolate continuous lines of rare subsets of lymphoid cells present in murine spleen in order to analyse their function and lineage relationship with respect to other lymphoid cells. Mitogenic stimulation was used to expand the lymphoid cells remaining in spleen following depletion of CD4+ and CD8+ T cells by antibody and complement treatment. Cells were cultured in the presence of concanavalin A (Con A),
interleukin-2
(
IL-2
) and syngeneic irradiated spleen feeder cells. This procedure expanded a population of non-T-, non-B-lymphoid cells bearing a common, unique phenotype resembling lymphoid precursors. Eight cloned lines from B10.A(2R) and B10.A(5R) strains of mice have been analysed here. Analysis of cell surface marker expression has revealed positive expression of class I and class II major histocompatibility complex (MHC) antigens, CD44, CD45 (T200 and B220) but expressing no markers unique to T, B or myeloid cells. All cell lines represent agranular lymphoblasts and show no evidence of early T-cell receptor (TcR) or Ig heavy chain gene rearrangements, suggesting no commitment to T-or B-lymphoid lineage. Despite expression of the NK1.1 marker for natural killer (NK) cells, none of the cell lines has been shown to have cytotoxic function for NK targets, nor could cytotoxic function be induced following various activation procedures. Analysis of lymphokine production has revealed no detectable IL-1,
IL-2
, IL-3, IL-4, IL-5, tumour necrosis factor-alpha (TNF-alpha) or
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) in cell supernatants. However, all but one of these cell lines constitutively produce IL-6. Each cell line has been shown to induce T-cell proliferation independently in mixed lymphocyte reactions, implicating the capacity of these cells to act as antigen-presenting cells. Consistent with this hypothesis is the observation that these cells also demonstrate endocytic activity for foreign proteins. This was visualized by their uptake of fluoresceinated albumin into cytoplasmic granules. Since they express many cell surface markers common to described isolates of spleen dendritic cells, including both class I and class II major histocompatibility molecules, they would appear to represent the first example of continuous lines of this rare cell subset.
...
PMID:Characterization of unique lymphoid cells derived from murine spleen which constitutively produce interleukin-6. 834 1
Tumor infiltrating lymphocytes (TIL) were cultured from 17 B-cell lymphoma specimens derived from patients with predominantly low-grade malignancies. Specimens included 15 lymph-node biopsies, 1 malignant pleural effusion, and PBL from 1 patient with circulating lymphoma cells. The phenotypic and proliferative characteristics of TIL cultured in
interleukin-2
(
IL-2
) were studied, as well as cytolysis and cytokine secretion in response to autologous tumor. Flow cytometry of fresh tumor suspensions showed that 50% of cells (median) were malignant B cells and 36% were infiltrating T lymphocytes. After culture for approximately 1 month, TIL were 75% +/- 8% CD3+ (mean +/- SEM), 47% +/- 8% CD4+ and 35% +/- 7% CD8+. TIL proliferation was modest in most cases: the median maximum expansion was 32-fold in 25 days. Lysis of autologous tumor in 4-hour 51Cr release assays was mediated by 2 of 12 TIL studied, but was nonspecific. However, these same two TIL, when cocultured with various tumor stimulators, preferentially secreted tumor necrosis factor-alpha and
granulocyte-macrophage colony-stimulating factor
after autologous tumor stimulation; unstimulated TIL secreted undetectable or barely detectable levels of these cytokines. In one TIL culture, cytokines were secreted by purified CD4+ TIL but not by CD8+ cells, and secretion was completely abrogated by the anti-major histocompatibility complex (MHC) class II antibody IVA12. Thus, although specific cytokine secretion by lymphoma TIL in response to autologous tumor was observed, it occurred in fewer than 20% of patients studied.
...
PMID:Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. 835 84
Transfected Jurkat cells overexpressing extracellular signal-regulated kinase (ERK1), also referred to as mitogen-activated protein (MAP) kinase, were selected by Western blotting assay using anti-ERK1 and antiphosphotyrosine antibodies in combination with a functional MAP kinase assay. We then asked whether enhanced ERK1 expression had any effect on induction of T-cell cytokine genes. The results show that overexpression of ERK1 enhances expression of T-cell
interleukin-2
(
IL-2
), IL-3, and
granulocyte-macrophage colony-stimulating factor
mRNA; no change was seen in expression of the alpha-actin gene. DNA-binding activities of the transcription factors AP1, NF-AT, and NF-kB were specifically increased twofold to fourfold in ERK1-overexpressing clones relative to nontransformed or vector-transformed cells, whereas no enhancement of CK1-CK2 protein DNA binding activity was detected after ERK1 overexpression. Additionally, increased NF-AT DNA binding activity was associated with functional enhancement of NF-AT transactivating activity in ERK1-overexpressing cells. These results provide direct evidence for the role of MAP kinase in the regulation of cytokine gene expression and indicate that such regulation is likely mediated through the enhanced DNA binding activity of specific nuclear transcription factors.
...
PMID:Overexpression of mitogen-activated protein kinase (ERK1) enhances T-cell cytokine gene expression: role of AP1, NF-AT, and NF-KB. 840 Feb 95
Crystal and NMR structures of helical cytokines--interleukin-4 (IL-4),
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
), and
interleukin-2
(
IL-2
)--have been compared. Root mean square deviations in the C alpha coordinates for the conserved regions of the helices were 1-2 A between different cytokines, about twice the differences observed for independently determined crystal and solution structures of IL-4. Considerable similarity in amino acid sequence in the areas expected to interact with the receptors was detected, and the available mutagenesis data for these cytokines were correlated with structure conservation. Models of cytokine-receptor interactions were postulated for IL-4 based on its structure as well as on the published structure of human growth hormone interacting with its receptors (de Vos, A.M., Ultsch, M., & Kossiakoff, A.A., 1992, Science 255, 306-312). Patches of positively charged residues on the surfaces of helices C and D of IL-4 may be responsible for the interactions with the negatively charged residues found in the complementary parts of the IL-4 receptors.
...
PMID:Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding. 840 Dec 23
The treatment of cancer with lymphokine-activated killer (LAK) cells in conjunction with high-dose
interleukin-2
(
IL-2
) has been limited by the toxicity of
IL-2
and the narrow range of tumors that respond to therapy. Cytokines that are capable of augmenting lower doses of
IL-2
are, therefore, a major focus of research. We report here that
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) can augment low-dose
IL-2
LAK induction from murine splenocytes. Anti-tumor necrosis factor alpha (anti-TNF alpha) or anti-interferon gamma (anti-IFN gamma) monoclonal antibodies did not inhibit (
IL-2
+
GM-CSF
)-induced LAK generation, indicating that
GM-CSF
augmentation does not require TNF alpha or IFN gamma activity. Depletion of natural killer cells before culture did not inhibit low-dose
IL-2
-induced LAK generation or the ability of
GM-CSF
to augment LAK generation. In contrast, depletion of both CD4+ and CD8+ T cells before culture inhibited the generation of LAK activity. However, depletion of only CD4+ T cells, or only CD8+ T cells, did not inhibit the generation of
IL-2
or (
IL-2
+
GM-CSF
) LAK activity. These results suggest that LAK precursors are present in both the CD4+ and CD8+ T-cell populations and suggest that the addition of
GM-CSF
to low-dose
IL-2
may result in the generation of T-derived LAK cells.
...
PMID:Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. 849 Jan 77
Feeding antigens induces an immunological unresponsiveness termed oral tolerance but under some conditions, for example following the administration of cyclophosphamide (CY), immunity can be induced. These observations have usually been made by studying antibody production and delayed hypersensitivity with little attention given to other measurements of cellular activation. We have therefore examined the lymphokines produced by T cells obtained after the induction of oral tolerance or intragastric priming. Cells isolated from the spleen and Peyer's patches (PP) of tolerized mice could secrete high levels of interferon-gamma (IFN-gamma) and moderate levels of
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) in response to antigen while
interleukin-2
(
IL-2
), IL-3 and IL-4 could not be detected. Mesenteric lymph node (MLN) cells of tolerized mice did not respond to antigen unless spleen adherent cells were added to the cultures where IFN-gamma and
GM-CSF
were produced. Intragastric priming was achieved by feeding antigen to CY-treated mice. T cells from the spleen, MLN and PP of these mice could produce
GM-CSF
, IFN-gamma, some IL-3 but little or no
IL-2
and IL-4. The ability of MLN cells to proliferate with antigen in vitro was low and corresponded to low
IL-2
production. Thus T cells from fed mice secrete a defined pattern of lymphokines which differs in tolerizing and priming regimes.
...
PMID:T-cell lymphokine response to orally administered proteins during priming and unresponsiveness. 849 70
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>